185 related articles for article (PubMed ID: 21727212)
1. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
[TBL] [Abstract][Full Text] [Related]
2. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
3. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Ammoun S; Flaiz C; Ristic N; Schuldt J; Hanemann CO
Cancer Res; 2008 Jul; 68(13):5236-45. PubMed ID: 18593924
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
5. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
[TBL] [Abstract][Full Text] [Related]
6. Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244.
Ammoun S; Ristic N; Matthies C; Hilton DA; Hanemann CO
Neurobiol Dis; 2010 Jan; 37(1):141-6. PubMed ID: 19804833
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
8. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
[TBL] [Abstract][Full Text] [Related]
9. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
Zhou L; Ercolano E; Ammoun S; Schmid MC; Barczyk MA; Hanemann CO
Neoplasia; 2011 Dec; 13(12):1101-12. PubMed ID: 22247700
[TBL] [Abstract][Full Text] [Related]
10. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
11. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
[TBL] [Abstract][Full Text] [Related]
12. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.
Ammoun S; Hanemann CO
Nat Rev Neurol; 2011 Jun; 7(7):392-9. PubMed ID: 21647202
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation.
Fraenzer JT; Pan H; Minimo L; Smith GM; Knauer D; Hung G
Int J Oncol; 2003 Dec; 23(6):1493-500. PubMed ID: 14612918
[TBL] [Abstract][Full Text] [Related]
15. Catalytically inactive SHIP2 inhibits proliferation by attenuating PDGF signaling in 3T3-L1 preadipocytes.
Artemenko Y; Gagnon A; Sorisky A
J Cell Physiol; 2009 Jan; 218(1):228-36. PubMed ID: 18814181
[TBL] [Abstract][Full Text] [Related]
16. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
Abouantoun TJ; MacDonald TJ
Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.
Terabe F; Kitano M; Kawai M; Kuwahara Y; Hirano T; Arimitsu J; Hagihara K; Shima Y; Narazaki M; Tanaka T; Kawase I; Sano H; Ogata A
Mod Rheumatol; 2009; 19(5):522-9. PubMed ID: 19568828
[TBL] [Abstract][Full Text] [Related]
18. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.
Patwardhan PP; Surriga O; Beckman MJ; de Stanchina E; Dematteo RP; Tap WD; Schwartz GK
Clin Cancer Res; 2014 Jun; 20(12):3146-58. PubMed ID: 24718867
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]